4//SEC Filing
Pienta Kenneth 4
Accession 0000899243-21-007232
CIK 0001645460other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 8:44 PM ET
Size
19.2 KB
Accession
0000899243-21-007232
Insider Transaction Report
Form 4
Pienta Kenneth
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-02-16$2.86/sh+16,000$45,760→ 18,000 total - Sale
Common Stock
2021-02-16$15.15/sh−16,000$242,422→ 2,000 total - Exercise/Conversion
Common Stock
2021-02-17$2.86/sh+1,280$3,661→ 3,280 total - Exercise/Conversion
Common Stock
2021-02-17$5.00/sh+2,994$14,970→ 6,274 total - Sale
Common Stock
2021-02-17$15.05/sh−4,274$64,345→ 2,000 total - Exercise/Conversion
Stock Option (right to buy)
2021-02-16−16,000→ 1,280 totalExercise: $2.86Exp: 2023-11-16→ Common Stock (16,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-02-17−1,280→ 0 totalExercise: $2.86Exp: 2023-11-16→ Common Stock (1,280 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-02-17−2,994→ 147,006 totalExercise: $5.00Exp: 2024-04-17→ Common Stock (2,994 underlying)
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 to $15.60, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017.
- [F5]The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017.
Documents
Issuer
Cue Biopharma, Inc.
CIK 0001645460
Entity typeother
Related Parties
1- filerCIK 0001571862
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 8:44 PM ET
- Size
- 19.2 KB